Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 11;10(1):25.
doi: 10.1038/s41572-024-00508-y.

Gastric neuroendocrine neoplasms

Giuseppe Lamberti  1   2 , Francesco Panzuto  3   4 , Marianne Pavel  5 , Dermot O'Toole  6   7 , Valentina Ambrosini  8   9 , Massimo Falconi  10 , Rocio Garcia-Carbonero  11   12 , Rachel P Riechelmann  13 , Guido Rindi  14   15 , Davide Campana  16   17
Affiliations
Review

Gastric neuroendocrine neoplasms

Giuseppe Lamberti et al. Nat Rev Dis Primers. .

Abstract

Gastric neuroendocrine neoplasms (gNENs) display peculiar site-specific features among all NENs. Their incidence and prevalence have been rising in the past few decades. gNENs comprise gastric neuroendocrine carcinomas (gNECs) and gastric neuroendocrine tumours (gNETs), the latter further classified into three types. Type I anatype II gNETs are gastrin-dependent and develop in chronic atrophic gastritis and as part of Zollinger-Ellison syndrome within a multiple endocrine neoplasia type 1 syndrome (MEN1), respectively. Type III or sporadic gNETs develop in the absence of hypergastrinaemia and in the context of a near-normal or inflamed gastric mucosa. gNECs can also develop in the context of variable atrophic, relatively normal or inflamed gastric mucosa. Each gNEN type has different clinical characteristics and requires a different multidisciplinary approach in expert dedicated centres. Type I gNETs are managed mainly by endoscopy or surgery, whereas the treatment of type II gNETs largely depends on the management of the concomitant MEN1. Type III gNETs may require both locoregional approaches and systemic treatments; NECs are often metastatic and therefore require systemic treatment. Specific data regarding the systemic treatment of gNENs are lacking and are derived from the treatment of intestinal NETs and NECs. An enhanced understanding of molecular and clinical pathophysiology is needed to improve the management and outcomes of patients' gNETs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. WHO Classification of Tumours Editorial Board. WHO Classification of Endocrine and Neuroendocrine Tumours (WHO, 2022).
    1. WHO Classification of Tumours Editorial Board. WHO Classification of Digestive Tumours (WHO, 2019).
    1. Rindi, G. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 33, 115–154 (2022). - PubMed - DOI
    1. Raj, N. et al. Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability. JCO Precis. Oncol. 2018, PO.17.00267 (2018). - PubMed
    1. Rindi, G., Luinetti, O., Cornaggia, M., Capella, C. & Solcia, E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104, 994–1006 (1993). - PubMed - DOI

MeSH terms

LinkOut - more resources

-